Bin Tian, Yumin Wu, Wenjie Zhang, Ruijuan Liu, Song Qu, Zhenying Zhang, Wenjun Yan
{"title":"肺切除术后利多卡因与舒芬太尼PCIA：一项随机对照试验。","authors":"Bin Tian, Yumin Wu, Wenjie Zhang, Ruijuan Liu, Song Qu, Zhenying Zhang, Wenjun Yan","doi":"10.2147/DDDT.S538226","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We investigated the efficacy and safety of lidocaine-based patient-controlled intravenous analgesia (PCIA), compared with sufentanil-based PCIA on postoperative pain and recovery quality in patients undergoing thoracoscopic lung surgery.</p><p><strong>Methods: </strong>We recruited 160 patients undergoing thoracoscopic lung surgery who were randomized to receive lidocaine-based PCIA (1.5 mg/kg/h) or sufentanil-based PCIA (2 μg/mL) within 48 hours postoperatively. The primary endpoint was visual analogue scores (VAS) pain scores at 6, 12, 24, and 48 hours postoperatively. Postoperative quality of recovery-15 (QoR-15) scores and other prespecified endpoints were also recorded.</p><p><strong>Results: </strong>VAS pain scores at rest and during coughing in the lidocaine group were significantly lower at 6, 12, and 24 hours postoperatively (<i>P</i><0.05), with no difference at 48 hours (<i>P></i>0.05). QoR-15 scores in the lidocaine group were higher on postoperative day (POD) 1 (<i>P</i><0.001) and POD2 (<i>P</i><0.001), with significant differences in the two dimensions of postoperative physical comfort and pain (<i>P</i><0.001). The lidocaine group also experienced a shorter time to first flatus, defecation, and ambulation (<i>P</i><0.05), with no difference in the length of postoperative hospitalization and thoracic drainage time (<i>P></i>0.05). The serum IL-6, TNF-α, IL-8, cortisol, and epinephrine concentrations were lower in the lidocaine group on POD1 and POD2 (<i>P</i><0.05). The incidence of postoperative nausea and vomiting in the lidocaine group was lower (<i>P</i><0.05), with no differences in other adverse events (<i>P</i>>0.05).</p><p><strong>Conclusion: </strong>Compared with sufentanil-based PCIA, lidocaine-based PCIA significantly relieved postoperative pain and improved recovery quality after thoracoscopic lung surgery with fewer postoperative adverse events, which is a considerable choice for postoperative analgesia.</p><p><strong>Trial registration: </strong>This study was retrospectively registered at the Chinese Clinical Trial Registry on March 1st, 2023 (number ChiCTR2300068840).</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"8541-8553"},"PeriodicalIF":5.1000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456753/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lidocaine-Based vs Sufentanil-Based PCIA After Pulmonary Resection Surgery: A Randomized Controlled Trial.\",\"authors\":\"Bin Tian, Yumin Wu, Wenjie Zhang, Ruijuan Liu, Song Qu, Zhenying Zhang, Wenjun Yan\",\"doi\":\"10.2147/DDDT.S538226\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>We investigated the efficacy and safety of lidocaine-based patient-controlled intravenous analgesia (PCIA), compared with sufentanil-based PCIA on postoperative pain and recovery quality in patients undergoing thoracoscopic lung surgery.</p><p><strong>Methods: </strong>We recruited 160 patients undergoing thoracoscopic lung surgery who were randomized to receive lidocaine-based PCIA (1.5 mg/kg/h) or sufentanil-based PCIA (2 μg/mL) within 48 hours postoperatively. The primary endpoint was visual analogue scores (VAS) pain scores at 6, 12, 24, and 48 hours postoperatively. Postoperative quality of recovery-15 (QoR-15) scores and other prespecified endpoints were also recorded.</p><p><strong>Results: </strong>VAS pain scores at rest and during coughing in the lidocaine group were significantly lower at 6, 12, and 24 hours postoperatively (<i>P</i><0.05), with no difference at 48 hours (<i>P></i>0.05). QoR-15 scores in the lidocaine group were higher on postoperative day (POD) 1 (<i>P</i><0.001) and POD2 (<i>P</i><0.001), with significant differences in the two dimensions of postoperative physical comfort and pain (<i>P</i><0.001). The lidocaine group also experienced a shorter time to first flatus, defecation, and ambulation (<i>P</i><0.05), with no difference in the length of postoperative hospitalization and thoracic drainage time (<i>P></i>0.05). The serum IL-6, TNF-α, IL-8, cortisol, and epinephrine concentrations were lower in the lidocaine group on POD1 and POD2 (<i>P</i><0.05). The incidence of postoperative nausea and vomiting in the lidocaine group was lower (<i>P</i><0.05), with no differences in other adverse events (<i>P</i>>0.05).</p><p><strong>Conclusion: </strong>Compared with sufentanil-based PCIA, lidocaine-based PCIA significantly relieved postoperative pain and improved recovery quality after thoracoscopic lung surgery with fewer postoperative adverse events, which is a considerable choice for postoperative analgesia.</p><p><strong>Trial registration: </strong>This study was retrospectively registered at the Chinese Clinical Trial Registry on March 1st, 2023 (number ChiCTR2300068840).</p>\",\"PeriodicalId\":11290,\"journal\":{\"name\":\"Drug Design, Development and Therapy\",\"volume\":\"19 \",\"pages\":\"8541-8553\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456753/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Design, Development and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DDDT.S538226\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S538226","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Lidocaine-Based vs Sufentanil-Based PCIA After Pulmonary Resection Surgery: A Randomized Controlled Trial.
Background: We investigated the efficacy and safety of lidocaine-based patient-controlled intravenous analgesia (PCIA), compared with sufentanil-based PCIA on postoperative pain and recovery quality in patients undergoing thoracoscopic lung surgery.
Methods: We recruited 160 patients undergoing thoracoscopic lung surgery who were randomized to receive lidocaine-based PCIA (1.5 mg/kg/h) or sufentanil-based PCIA (2 μg/mL) within 48 hours postoperatively. The primary endpoint was visual analogue scores (VAS) pain scores at 6, 12, 24, and 48 hours postoperatively. Postoperative quality of recovery-15 (QoR-15) scores and other prespecified endpoints were also recorded.
Results: VAS pain scores at rest and during coughing in the lidocaine group were significantly lower at 6, 12, and 24 hours postoperatively (P<0.05), with no difference at 48 hours (P>0.05). QoR-15 scores in the lidocaine group were higher on postoperative day (POD) 1 (P<0.001) and POD2 (P<0.001), with significant differences in the two dimensions of postoperative physical comfort and pain (P<0.001). The lidocaine group also experienced a shorter time to first flatus, defecation, and ambulation (P<0.05), with no difference in the length of postoperative hospitalization and thoracic drainage time (P>0.05). The serum IL-6, TNF-α, IL-8, cortisol, and epinephrine concentrations were lower in the lidocaine group on POD1 and POD2 (P<0.05). The incidence of postoperative nausea and vomiting in the lidocaine group was lower (P<0.05), with no differences in other adverse events (P>0.05).
Conclusion: Compared with sufentanil-based PCIA, lidocaine-based PCIA significantly relieved postoperative pain and improved recovery quality after thoracoscopic lung surgery with fewer postoperative adverse events, which is a considerable choice for postoperative analgesia.
Trial registration: This study was retrospectively registered at the Chinese Clinical Trial Registry on March 1st, 2023 (number ChiCTR2300068840).
期刊介绍：
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
